A major obstacle in the systemic treatment of advanced malignant melanoma is its intrinsic resistance to conventionally used chemotherapeutic agents. In order to investigate the mechanisms of this intrinsic resistance, we have previously utilized retroviral insertional mutagenesis on an early-stage, drug sensitive human melanoma cell line (WM35) to establish mutated cell lines that exhibited increased resistance to cis-diamminedichloroplatinum(II) (CDDP). Here, we demonstrate that this increased resistance to CDDP is mediated by the over-expression of tyrosinase-related protein-2 (TYRP2), an enzyme that normally functions in the biosynthesis of the pigment, melanin. Northern and Western blot analyses revealed that the expression of TYRP2 in the virally-derived cell lines as well as in a panel of human melanoma cell lines positively correlated with their levels of resistance to CDDP. Furthermore, enforced expression of TYRP2 in WM35 cells by transfection elevated their resistance to CDDP. The increased CDDP resistance in the virally-derived clones and TYRP2 transfectants was accompanied by a reduction in CDDP-induced apoptosis. Interestingly, the virally-derived CDDP-resistant clones also showed cross resistance to carboplatin and methotrexate, but not taxol, suggesting that TYRP2 over-expression may confer resistance speci®cally to DNA damaging agents.
A major obstacle in the systemic treatment of advanced malignant melanoma is its intrinsic resistance to conventionally used chemotherapeutic agents. In order to investigate the mechanisms of this intrinsic resistance, we have previously utilized retroviral insertional mutagenesis on an early-stage, drug sensitive human melanoma cell line (WM35) to establish mutated cell lines that exhibited increased resistance to cis-diamminedichloroplatinum(II) (CDDP) . Here, we demonstrate that this increased resistance to CDDP is mediated by the over-expression of tyrosinase-related protein-2 (TYRP2), an enzyme that normally functions in the biosynthesis of the pigment, melanin. Northern and Western blot analyses revealed that the expression of TYRP2 in the virally-derived cell lines as well as in a panel of human melanoma cell lines positively correlated with their levels of resistance to CDDP. Furthermore, enforced expression of TYRP2 in WM35 cells by transfection elevated their resistance to CDDP. The increased CDDP resistance in the virally-derived clones and TYRP2 transfectants was accompanied by a reduction in CDDP-induced apoptosis. Interestingly, the virally-derived CDDP-resistant clones also showed cross resistance to carboplatin and methotrexate, but not taxol, suggesting that TYRP2 over-expression may confer resistance speci®cally to DNA damaging agents.
Overall, these results demonstrate a novel mechanism of drug resistance in human melanoma cells that is mediated by the over-expression of TYRP2. Since TYRP2 is expressed only in cells of melanocytic lineage, this may represent the ®rst report of a lineage-speci®cIntroduction Intrinsic (de novo) resistance to chemotherapeutic drugs is a common characteristic of malignant melanoma and remains a major obstacle in the eective clinical management of this disease. In fact, patients with disseminated malignant melanoma often face a very poor prognosis, with a medial survival of approximately 6 months (Balch et al., 1989) , and less than 10% of patients surviving beyond 5 years after the initial diagnosis (Ho, 1995) .
Several drug resistance mechanisms have been well characterized in various malignancies. For example, the multidrug resistance-associated protein (MRP) (Cole et al., 1992) and P-glycoprotein (Kartner et al., 1986) have been shown to function as transmembrane eux pumps that prevent the accumulation of drugs in the cell. The glutathione/glutathione S-transferase (GSH/GST) detoxi®cation system (Batist et al., 1986) protects cancer cells from cytotoxic damage by conjugating with the chemotherapeutic compounds. Furthermore, the differential expression of various oncogenes, such as Bcl-2, Ras and p53, have been shown to confer chemoresistance (Koo et al., 1999; Samuelson and Lowe, 1997) . For example, Jansen et al. (1998) have recently shown that approximately 90% of human melanomas express Bcl-2 and that the treatment of human melanoma tumors in immunode®cient mice with Bcl-2 antisense oligonucleotide improves chemosensitivity to dacarbazine. However, the mechanisms on intrinsic drug resistance in melanomas remain poorly understood.
In an attempt to identify gene(s) that confer resistance to cis-diamminedichloroplatinum(II) (CDDP), a commonly used DNA-alkylating chemotherapeutic agent, we have previously utilized the strategy of retroviral insertional mutagenesis on an early-stage, CDDPsensitive human melanoma cell line, WM35 (Lu et al., 1995) . This approach was based on the random integration of proviruses into the host cell genome, thereby activating or inactivating cellular genes depending on the site of integration. The use of retroviral insertional mutagenesis has previously been shown to be eective in the identi®cation of oncogenes and tumor suppressor genes in various animal tumor systems induced by slow transforming retroviruses (Kung et al., 1991; Peters, 1986) .
The rationale for our studies was that by utilizing this technique on CDDP-sensitive WM35 cells, a gene involved in the acquisition of CDDP resistance may be mutated or activated, leading to the expression of CDDP resistance, a dominantly selectable phenotype. By this method, we successfully established nine independently derived CDDP-resistant clones (Lu et al., 1995) . Analysis of the retroviral¯anking sequences revealed that ®ve of these clones had acquired an identical retroviral integration site which was designated as`CDDP Resistance Locus 1' (CRL-1). These clones with CRL-1 rearrangement showed approximately a 2 ± 3-fold increase in the level of CDDP resistance relative to the parental WM35 cells (Lu et al., 1995) . Since changes in tumor sensitivities in the range of 2 ± 5-fold can account for loss of tumor responsiveness to chemotherapeutic drugs (Young, 1989; Kuroda et al., 1991) , dierences of this magnitude may be clinically relevant.
Here, we report the characterization of these CDDPresistant variants and the identi®cation of the melanocyte-speci®c enzyme tyrosinase-related protein-2 (TYRP2) as a possible mediator of CDDP resistance in human melanoma cells.
Results
We have previously established several clonal cell lines that exhibited increased resistance to CDDP relative to their parental WM35 cell line by retroviral insertional mutagenesis (Lu et al., 1995) . Five of the nine independently derived CDDP-resistant clones (Clones B, D, E, F, G) had acquired the integration of a single provirus at the same site as revealed by the isolation of retroviral¯anking sequences, which we have designated CDDP Resistance Locus 1' (CRL-1). Of these, Clones E and G were selected for subsequent analysis.
Reduction of CDDP-induced apoptosis in CDDP-resistant cells
The mechanism of action of CDDP, as well as other DNA alkylating agents involves the generation of DNA damage and the subsequent induction of apoptosis. We therefore sought to determine if the increased resistance of the retrovirally-derived cell lines to CDDP was associated with a decrease in the number of cells undergoing apoptosis following CDDP treatment, relative to WM35. First, the cleavage of the 116 kDa polyADP-ribose-polymerase (PARP) into its 85 kDa subunit, a caspase-dependent process that is indicative of apoptosis (Lazebnik et al., 1994) , was determined in WM35 and Clone E cells treated for 24 h with 15 mM CDDP. Western blot analysis revealed that PARP was extensively cleaved in WM35 cells, particularly at 18 and 24 h of CDDP treatment, while Clone E cells exhibited very low levels of PARP cleavage (Figure 1a) . These results were supported by DNA fragmentation analysis. ELISA, using antibodies that recognize monoand oligonucleosome fragments produced in apoptotic cells, showed that the levels of apoptosis in WM35 cells following 15 mM CDDP treatment for 18 h were 4 ± 5 Figure 2 Cross-resistance of retrovirally-derived CDDP-resistant cells to carboplatin and methotrexate, but not taxol. WM35 and retrovirally-derived, CDDP-resistant Clone E and G cells were treated with various concentrations of (a) carboplatin; (b) methotrexate; and (c) taxol for 18 h. Both Clones E and G showed higher resistance to carboplatin and methotrexate, but were equally sensitive to taxol, relative to WM35 cells times greater than in Clone E (Figure 1b) . Together, these results demonstrate that the increased resistance to CDDP in the retrovirally-derived cell lines is associated with a reduction in the levels of apoptosis following CDDP treatment.
Cross resistance of CDDP-resistant cells lines to carboplatin and methotrexate, but not taxol A striking feature of many CDDP-resistant cell lines is their cross-resistance to a wide variety of chemotherapeutic agents. To determine if the retrovirally-derived CDDP-resistant clones also exhibit cross-resistance to other chemotherapeutic agents, we treated WM35, and Clones E and G with various doses of carboplatin, methotrexate and taxol for 24 h. Clones E and G both showed increased resistance to carboplatin ( Figure 2a ) and methotrexate ( Figure 2b ) compared to WM35. However, Clones E and G were found to be equally sensitive to taxol as WM35 (Figure 2c ).
Increased expression of TYRP2 in retrovirally-derived CDDP-resistant cell lines
In order to identify the gene(s) that are dierentiallyexpressed following proviral integration, subtractive hybridization was performed on mRNA isolated from WM35 and Clone E cells. By this approach, 89 clones were isolated. Of these, three clones, c65, c80 and c83, were con®rmed to be substantially up-regulated in Clones E and G cells relative to WM35 by Northern blot analysis (Figure 3a ). DNA sequencing revealed that c80 represented portions of the MSCV retrovirus used for the initial infection. However, clones c65 and c83 were both 100% homologous to the 3'-untranslated region of the melanocyte-speci®c, tyrosinase-related protein-2 (TYRP2) mRNA. Subsequent analysis showed that TYRP2 was up-regulated at the mRNA and protein levels in each of the seven retrovirallyderived CDDP-resistant cell lines examined (Figure  3b,c) .
Levels of TYRP2 expression correlates with CDDP resistance in human melanoma cell lines
To determine the possible relationship between TYRP2 expression and CDDP resistance, a panel of human melanoma cells were analysed for TYRP2 expression. As shown in Figure 4a , the levels of TYRP2 were variable among the dierent cell lines examined. For example, the cell line WM1341B, a vertical growth phase human melanoma cell line, constitutively TYRP2 mRNA expression was elevated in each of the seven retrovirally-derived CDDP-resistant cell lines relative to the WM35 parental cell line. Levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used to assess uniformity of RNA loading per lane. (c) Western blot analysis showed that TYRP2 protein expression (both the 75 kDa glycosylated form and 55 kDa precursor form) was also elevated in each of the CDDP-resistant clones compared to WM35. Uniformity of protein loading per lane was assessed by measuring the levels of extracellular signal-regulated kinase 2 (ERK-2) TYRP2-mediated drug resistance W Chu et al expressed very high levels of TYRP2, whereas WM9, a metastatic human melanoma cell line, showed very low levels of TYRP2 expression.
To determine if the constitutive levels of TYRP2 in these cells correlated with their sensitivities to CDDP, they were treated with various concentrations of CDDP for 24 h. The cell lines WM1341B and Clone E, both of which express high levels of TYRP2, were found to be more resistant to the cytotoxic eects of CDDP than WM35 (Figure 4b ). Conversely, WM9, which express very low levels of TYRP2, was signi®cantly more sensitive to CDDP treatment than WM35. These results demonstrate that the constitutive levels of TYRP2 expression positively correlate with CDDP resistance in a variety of human melanoma cells.
Enforced expression of TYRP2 by transfection confers increased CDDP resistance A 2.1 kb cDNA fragment of human TYRP2, which included the entire open reading frame, was cloned into the pcDNA3 expression vector and transfected into WM35 cells. Figure 5a shows the levels of TYRP2 protein in several of the transfectant cell lines. Each transfectant expressed higher levels of TYRP2 relative to the parental WM35 cell line, some exhibiting levels of TYRP2 comparable to Clone E. Three of the transfectants C4, C8 and C9, were tested for their relative sensitivities to CDDP. Treatment with 0-20 mM The TYRP2 transfectants C4, C8 and C9 were treated with various doses of CDDP for 24 h, followed by cell viability measurement by the MTS assay. Each of the TYRP2 transfectants showed increased resistance to CDDP compared to the parental WM35 cell line. (c) Clones C4, C8 and C9 also showed decreased levels of CDDP-induced apoptosis relative to WM35 and vector alone transfectants when treated for 18 h with 15 mM CDDP. Data are presented as mean+s.d.; n=3 TYRP2-mediated drug resistance W Chu et al CDDP for 24 h showed that C4, C8 and C9 were each more resistant to CDDP than WM35 at each dose ( Figure 5b ). Thus, these ®ndings suggest that the upregulation of TYRP2 alone is sucient to confer increased resistance to CDDP. Additionally, the TYRP2 transfectants showed decreased levels of CDDP-induced apoptosis compared to WM35 and vector alone transfectants when treated for 18 h with 15 mM CDDP (Figure 5c ).
TYRP2 is not expressed in a panel of non-melanoma human cancer cell lines
The expression of TYRP2 is known to be limited to cells of neural crest lineage. These include various tissues of the central nervous system such as substantia nigra, forebrain and midbrain, as well as melanocytes and melanoma cells (Orlow et al., 1995; Bernd et al., 1994; Tief et al., 1998) . Since cancer cells can often ectopically express genes that are characteristic of other cell lineages, we examined a panel of non-melanoma human cancer cell lines for the expression of TYRP2. Among the human colon (DLD-1; HT29), gastric (MKN-45; MKN-74; N87; TMK1), ovarian (SKOV3), prostate (DU145; LNCaP; PC3), breast (HBL100) and epidermoid carcinoma (A431) cell lines analysed, no TYRP2 expression was detected ( Figure  6 ). These results suggest that TYRP2 is speci®cally expressed in melanoma cells, and not in nonmelanocytic cancer cell lines.
Discussion
Mechanisms of drug resistance in cancer cells have been vigorously studied in both in vitro and in vivo systems. They are multifaceted and complex, and can include the involvement of membrane-associated eux pumps, the up-regulation of cellular detoxifying thiols, enhanced DNA repair activity and the inhibition of apoptotic pathways (Ishikawa et al., 1994; Andrews et al., 1985; Lai et al., 1988 Lai et al., , 1989 Chu, 1994; Chu and Chang, 1990; Zhen et al., 1992; Miyake et al., 1998; Citro et al., 1998) . In many malignancies, drug resistance is acquired through prolonged and repeated exposure to a chemotherapeutic agent. However, many tumors express an inherent or intrinsic resistance to chemotherapeutic compounds, rendering them generally unresponsive to maximum tolerated doses of chemotherapy that can be achieved clinically. Intrinsic drug resistance is characteristically commonly encountered in human malignant melanoma, and remains a major obstacle in the treatment of this disease. Therefore, elucidating the mechanisms of drug resistance in melanoma cells remains an important undertaking for the eventual development of more eective treatment strategies.
With this goal in mind, we have previously established several CDDP-resistant cell lines from an early-stage, CDDP-sensitive human melanoma cell line, WM35, by retroviral insertional mutagenesis, and have shown that these variants express a 2 ± 3-fold increase in their resistance to CDDP (Lu et al., 1995) . We have also shown that ®ve of these clones had acquired the integration of a single provirus at the same site, designated CRL-1. Analysis of approximately 20 kb of genomic DNA¯anking the proviral integration site failed to identify possible exonic sequences whose expressions were altered as a result of proviral insertion. This was not unexpected, since proviruses can often alter the expressions of target genes located as much as 80 kb from the site of integration (Bartholomew et al., 1989) . Thus, to identify the target gene(s) of proviral integration at CRL-1, we compared overall dierences in gene expression between the parental WM35 cells and virally-derived clones by subtractive hybridization. Using this approach, we demonstrated that these virally-derived CDDP-resistant clones consistently over-expressed the melanocyte-speci®c enzyme, tyrosinase-related protein-2 (TYRP2). We also showed that this correlation between TYRP2 overexpression and CDDP resistance was not limited to cells derived from WM35, but included a variety of human melanoma cell lines. For example, the cell line WM1341B, which constitutively expresses high levels of TYRP2 was shown to be signi®cantly more resistant to CDDP than WM35. Similarly, the cell line WM9, which expresses very low levels of TYRP2 exhibited greater sensitivity to CDDP treatment compared to WM35. Moreover, enforced overexpression of TYRP2 in WM35 cells by transfection resulted in increased resistance to CDDP in the TYRP2 transfectants. Thus, these results strongly suggest that TYRP2 may be an important mediator of CDDP-resistance in human melanoma cells. However, we have yet to determine whether TYRP2 is the direct target of proviral integration at CRL-1, or a gene that is up-regulated as a result of CRL-1 rearrangement.
TYRP2, also known as L-DOPAchrome tautomerase, is an enzyme that has been well characterized for its function in non-decarboxylative tautomerization of L-DOPAchrome to the highly stable product 5,6-dihydroxyindole-2-carboxylic acid (DHICA) in the melanin biosynthetic pathway in melanocytes (Leonard et al., 1988; Aroca et al., 1990; Pawelek, 1990; Tsukamoto et al., 1992; Jackson et al., 1992) . TYRP2, along with the enzymes tyrosinase and TRYP1, comprise the tyrosinase family of proteins, and LNCaP; PC3), breast (HBL100) and epidermoid carcinoma (A431) were assessed for TYRP2 expression. Northern blot analysis revealed that TYRP2 was not expressed in any of the non-melanoma cell lines examined. Ticks denote the relative migrations of 28S and 18S ribosomal RNA TYRP2-mediated drug resistance W Chu et al represent the principal enzymes involved in the synthesis of melanin. Tyrosinase, TRYP1 and TYRP2 are considered markers of melanocyte dierentiation and their expressions are characteristic of terminally dierentiated melanocytes. However, studies have shown that these proteins are also expressed at various levels in human melanoma cells, and serve as melanoma-associated antigens which have been extensively targeted in immunotherapeutic strategies for treating malignant melanoma (Overwijk et al., 1999; Parkhurst et al., 1998; Kawakami et al., 1998) . Although the expressions of tyrosinase and TRYP1 have been shown to be variable among dierent melanoma cells, TYRP2 has been reported to be consistently up-regulated. For example, Orlow and colleagues (1995) have shown that TYRP2 was the only member of the tyrosinase family of proteins that was clearly present in each primary and metastatic tumor sample examined. However, the possible relationship between TYRP2 expression and drug resistance in melanoma has not been previously explored. Based on these observations and the results presented in this study, we suggest that the overexpression of TYRP2 may be an important mediator of intrinsic drug resistance in melanoma cells.
Interestingly, TYRP2-mediated drug resistance in the virally-derived clones was not limited to CDDP, but included carboplatin and methotrexate, but not taxol. CDDP and carboplatin are platinum compounds that both exert their anti-neoplastic eects by forming DNA adducts and crosslinks, leading to apoptotic cell death. Methotrexate, on the other hand, is a speci®c inhibitor of the enzyme dihydrofolate reductase (DHFR) and acts by limiting the synthesis of purine and pyrimidine nucleotides, thereby impairing DNA repair and eventually leading to methotrexate-induced single-and double-strand breaks (Lorico et al., 1988; Borchers et al., 1990) . Thus, CDDP, carboplatin and methotrexate each in¯ict apoptotic death of cancer cells by inducing DNA damage. Conversely, the mechanism of taxol-induced apoptosis is independent of DNA and involves the stabilization of microtubules, which blocks cells in the G2/M checkpoint of the cell cycle. Therefore, in light of our observations of crossresistance of TYRP2 over-expressing, CDDP-resistant cells to carboplatin and methotrexate, but not taxol, we suggest that TYRP2-mediated drug resistance may be relevant to compounds that induce DNA damage.
This study represents the ®rst report of a possible function for TYRP2 in melanoma chemoresistance. Although we have yet to determine the exact mechanism by which TYRP2 over-expression confers drug resistance, based on the data presented and previously published results, several distinct possibilities exist. First, the reduction of CDDP-induced apoptosis in both the virally-derived and TYRP2 transfected cells suggests that TYRP2 may play a role in modulating apoptotic pathways, either by suppressing the actions of pro-apoptotic genes and/or by augmenting the activities of anti-apoptotic genes or DNA repair enzymes. Moreover, since cross-resistance was observed for DNA-targeting compounds, but not for agents that target microtubules, the possibility of TYRP2 functioning to enhance DNA repair remains distinct. Indeed, the DNA repair protein O6-alkylguanine-DNA alkyltransferase has been postulated to be an important mediator of resistance to alkylating agents (Dolan et al., 1999; Moriwaki et al., 1992) . Thus, it remains possible that TYRP2 over-expression may increase the activities of this, or other DNA repair enzymes.
Many of the previously described mechanisms of drug resistance are widely applicable to a variety of hematopoietic malignancies and solid tumors. For example, the expressions and activities of the well characterized P-glycoprotein (Kartner et al., 1986 ) and the multidrug resistance-associated protein (MRP) (Cole et al., 1992) have been described in leukemia, small cell lung cancer, retinoblastoma and colorectal carcinoma, among others (Legrand et al., 1998; Chan et al., 1997; Fillpits et al., 1997) . The expression of TYRP2, on the other hand, has been shown to be limited to cells of melanocytic lineage in normal tissues. In addition, although TYRP2 has previously been shown to be highly expressed in melanoma cells, we have demonstrated that TYRP2 is not expressed in a variety of non-melanoma human cancer cell lines. Thus, our report of resistance mediated by TYRP2 over-expression in melanoma cells represents, to our knowledge, the ®rst report of a lineage-speci®c mechanism of drug resistance. This may have signi®cant clinical implications, since the speci®c targeting of TYRP2 for chemosensitization therapies should have minimal eects, if any, on non-melanocytic cells.
In summary, we have demonstrated that the levels of TYRP2 expression in human melanoma cells positively correlated with their resistance to CDDP and other DNA targeting chemotherapeutic compounds, and that the enforced over-expression of TYRP2 in CDDPsensitive cells can render them more resistant to CDDP. Moreover, we have shown that this increased resistance to CDDP is associated with a decrease in CDDP-induced apoptosis. Overall, these results strongly implicate TYRP2 as an important and novel mediator of drug resistance in human melanoma cells. Given that human melanomas are often found to express high levels of TYRP2, these ®ndings may provide a possible molecular basis for intrinsic drug resistance in malignant melanoma. Thus, TYRP2 may serve as a potential novel target for therapeutic strategies to render malignant melanoma more sensitive to DNA damaging agents.
Materials and methods

Cells and culture conditions
All human melanoma cell lines were generously provided by Dr Meenhard Herlyn (Wistar Institute, Philadelphia, PA, USA). The CDDP-resistant variants of WM35 (Clones A-I) were established by retroviral insertional mutagenesis of WM35 cells as described previously (Lu et al., 1995) . Cells were routinely maintained in RPMI 1640 media supplemented with 5% FBS (Life Technologies) at 378C in a humidi®ed atmosphere of 95% air : 5% CO 2 .
DNA fragmentation assay
Levels of apoptosis were determined by determining the quantities of DNA fragmentation using the Cell Death Detection ELISA Plus kit (Boehringer Mannheim). Brie¯y, cells were plated in 96-well plates at a density of 1610 4 cells/ TYRP2-mediated drug resistance W Chu et al well and allowed to attach overnight. Cells were treated with 15 mM CDDP for 18 h and then lysed. Cell lysates were transferred to streptavidin-coated plates and used for ELISA analysis using anti-histone-biotin and anti-DNA POD antibodies.
Cytotoxicity assay
The number of viable cells following drug treatment was assessed using the CellTiter 96 Aq ueous Non-Radioactive MTS Cell Proliferation Assay (Promega). Brie¯y, 1610 4 cells/well were plated in 96-well plates, allowed to attach overnight and then administered chemotherapeutic agents at various concentrations for 24 h. Four hours prior to harvest, MTS/ phenazine methosulfate was added to the cells and the number of viable cells was determined by measuring the quantity of formazan by spectrophotometric analysis at 490 nm.
Subtractive hybridization
Subtractive hybridization was performed using the PCRSelect cDNA Subtraction Hybridization kit (Invitrogen) as outlined by the manufacturer. Candidate cDNAs were cloned into pCR2.1 plasmid vectors by TA cloning (Invitrogen) and were sequenced as probes for Northern blot analysis. DNA sequences were compared to existing sequences in the GenBank database.
Northern blot analysis
Total RNA was extracted from cultured cells using the Trizol 2 (Life Technologies) reagent. RNA extracts were quanti®ed by spectrophotometric analysis and 10 mg of each extract were fractionated on 1% agarose/formaldehyde gels and transferred to nylon ®lters (ZetaProbe, BioRad Laboratories). Prehybridization and hybridization with 32 Plabeled cDNA probes were performed at 428C in 50% formamide, 5X SSPE, 1X Denhardt's solution, 5% dextran sulfate and 1% SDS. Blots were washed with high stringency at 658C and exposed onto X-ray ®lm.
SDS ± PAGE and Western blotting
Cell lysates were prepared in 50 mM Tris, pH 7.4, 50 mM NaCl, 2 mM MgCl 2 , 1 mM EDTA, 0.5% IGEPAL CA-630 and protease inhibitors (0.1 mM PMSF, 100 mM sodium vanadate, 20 mg/ml leupeptin, 20 mM NaF 2 , 1 mM benzamide). Protein extracts were resolved by SDS-polyacrylamide gel electrophoresis, immunoblotted with polyclonal antibodies at the appropriate dilutions, and immunoreactivity was detected by enhanced chemiluminescence (Amersham). The aPEP8 polyclonal antibody against human TYRP2 (provided by Dr Vincent Hearing, Western General Hospital, Edinburgh, UK) recognizes both the glycosylated (75 kDa) and precursor form (55 kDa) of TYRP2 .
Establishment of TYRP2 transfectants of WM35
A 2.1 kb cDNA fragment of human TYRP2 (kindly provided by Dr Rick Sturm, University of Queensland, Australia) which includes the entire open reading frame, was cloned into the pcDNA3 expression vector (Invitrogen) and transfected into WM35 cells using Lipofectin (Life Technologies). Transfected cells were selected with 800 mg/ml geneticin (Life Technologies) for more than 2 weeks. Cells resistant to geneticin were individually subcloned and expanded in culture.
